The Food and Drug Administration (FDA) has approved a new presentation of Selarsdi ™ (ustekinumab-aekn), a biosimilar to Stelara ® (ustekinumab), expanding the product’s indications to include ...
Ethiqa XR now includes captive rodents and laboratory rabbits for 72-hour post-procedural pain management on its label ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback